Last reviewed · How we verify
Complicated Skin and Skin Structure Infection
Approved treatments
- Tygacil · Fresenius Kabi
Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis. - Avelox · Bayer AG
Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms. - Pipracil
Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. - Tygacil · Pfizer
Tigecycline is a tetracycline class antibacterial agent. - Avelox · Novartis Pharmaceuticals
- Merrem · National Institutes of Health Clinical Center (CC)
- Invanz · Merck & Co.
Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Merrem · Pfizer
Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Vibativ · Cumberland
Vibativ works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death. - Zosyn · Merck Sharp & Dohme B.V.
Zosyn works by blocking bacterial enzymes that break down antibiotics, allowing the antibiotics to kill bacteria more effectively. - Noroxin
- Floxin
- Vibativ · Cumberland
- Levaquin · Generic (originally Daiichi Sankyo/J&J)
Levofloxacin is a fluoroquinolone antibacterial agent. - Ofloxacine · Assistance Publique - Hôpitaux de Paris
Clinical guidelines
- FDA label — 1L
Tigecycline for injection is indicated for the treatment of complicated skin and skin structure infections caused by susceptible isolates of various bacteria. - FDA label — 1L
Tigecycline for injection is indicated for the treatment of complicated intra-abdominal infections caused by susceptible isolates of various bacteria. - FDA label — 1L
Tigecycline for injection is indicated for the treatment of community-acquired bacterial pneumonia caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Complicated Skin and Skin Structure Infection patent landscape — cliff calendar, originator estates, attackable patents
- Complicated Skin and Skin Structure Infection treatment landscape brief
- Complicated Skin and Skin Structure Infection treatment updates RSS
Frequently asked questions about Complicated Skin and Skin Structure Infection
What drugs treat Complicated Skin and Skin Structure Infection?
Tracked treatments include Tygacil, Avelox, Pipracil, Merrem, Invanz, Vibativ, Zosyn, Noroxin.
What is the treatment for Complicated Skin and Skin Structure Infection?
Standard treatment for Complicated Skin and Skin Structure Infection includes Tygacil, Avelox, Pipracil, Merrem, Invanz. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Complicated Skin and Skin Structure Infection?
FDA label publishes guidelines for Complicated Skin and Skin Structure Infection. 3 guideline references tracked.
Related
- Treatment landscape: Complicated Skin and Skin Structure Infection patent cliff · Complicated Skin and Skin Structure Infection CI report
- Treatment: Tygacil · Fresenius Kabi
- Treatment: Avelox · Bayer AG
- Treatment: Pipracil
- Treatment: Tygacil · Pfizer
- Treatment: Avelox · Novartis Pharmaceuticals
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing